Signaling Networks and Cell Cycle Control

1 Integrin Signaling.- 2 Signal Transduction Through Tyrosine Kinase Growth Factor Receptors.- 3 Signaling from TGF-? Receptors.- 4 The Wnt Signal Transduction Pathway.- 5 Signaling from G-Protein-Coupled Receptors to the Nucleus.- 6 Proximal Events in T-Cell Activation.- 7 Signal Transduction from the High Affinity IgE Receptor.- 8 Signaling Through Fas (CD95, APO-1) and Related Death Receptors.- 9 Signal Transduction to the Nucleus by MAP Kinase.- 10 The Regulation of MAP Kinase Pathways by MAP Kinase Phosphatases.- 11 Control of MAPK Signaling by Ste20- and Stel 1-Like Kinases.- 12 Ras Signaling and Transformation.- 13 Signaling Pathways Controlled by Rho Family GTP-Binding Proteins.- 14 PI3-Kinases: Role in Signal Transduction.- 15 PI3K-Related Kinases: Roles in Cell-Cycle Regulation and DNA Damage Responses.- 16 Integrative Signaling Through c-Abl: A Tyrosine Kinase with Nuclear and Cytoplasmic Functions.- 17 Src: A Model for Regulation of Intracellular Signaling Molecules.- 18 Inhibitors of Protein Kinase C and Related Receptors for the Lipophilic Second Messenger sn-1,2-Diacylglycerol.- 19 Reactive Oxygen Species in Proliferative Signaling.- 20 Sphingolipid Metabolites in Signal Transduction.- 21 The Jak/Stat Signaling Cascade: Its Role in the Biological Effects of Interferons.- 22 Regulation of Cell Growth and Death by p53.- 23 Regulation of NF-?B Function: Novel Molecular Targets for Pharmacological Intervention.- 24 Using Protein—Interaction Domains to Manipulate Signaling Pathways.- 25 Protein Tyrosine Kinase Inhibitors as Novel Therapeutic Agents.- 26 A Pharmacological Approach to the MAP Kinase Cascade.- 27 Specific Inhibitors of p38 MAP Kinase.- 28 Farnesyltransferase Inhibitors: Anti-Ras or Anticancer Drugs?.- 29 Targeted p53 Gene Therapy-MediatedRadiosensitization and Chemosensitization.- 30 Treatment of p53-Deficient Cancers by Adenovirus E1B-Region Mutants: From Basic Research to the Clinic.- 31 The Cell Cycle Inhibitor p27 as a Prognostic Marker in Human Tumors and a Novel Target for Therapeutic Intervention.- 32 Chemical Cyclin-Dependent Kinase Inhibitors: Therapeutic Implications.